Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMM 1 104 (Primary) ; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Ductal carcinoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Immuneering

    • Most Recent Events

    • 07 May 2024 According to an Immuneering Corporation media release, results from the Phase 1 portion of this Phase 1/2a study presented at the American Association for Cancer Research (AACR) Annual Meeting.
    • 14 Mar 2024 According to an Immuneering Corporation media release, company plans to present further data from the ongoing Phase 1 portion of its Phase 1/2a study of IMM-1-104 in advanced RAS-mutant solid tumors at a future medical meeting.
    • 14 Mar 2024 According to an Immuneering Corporation media release, company expect to report initial data from multiple arms of this Phase 2a portion in 2024, and look forward to sharing that data later this year. The Phase 1 portion is being conducted at five clinical sites in the United States. The Phase 2a portion is expected to include up to twenty clinical sites and has already dosed its first patient.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top